Bausch Health Companies Inc. BHC
Deals with insiders in the proxy filed Apr 8, 2026
Proxy, Item 404Deals between BHC and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 2, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 2, 2025.
Nothing new: every deal in this year's section was reported last year too.
No longer reported 1 paragraph of the proxy filed Apr 2, 2025 with nothing like them this year
Certain Related-Party Transactions“Since January 1, 2024, there were no related-party transactions required to be reported pursuant to relevant SEC rules in this proxy statement.”
Read it in last year's proxyopen_in_new
New wording of the review policy 4 paragraphs without an amount or a name
Certain Related-Party Transactions“Since January 1, 2025, the Company was involved in the following related-party transactions, which have been approved or ratified by either the Audit and Risk Committee or the Board:”
Read it in the proxyopen_in_new
Director Appointment and Nomination Agreement“On February 24, 2021, the Company entered into a Director Appointment and Nomination Agreement (“Nomination Agreement”) with Carl C. Icahn, Brett M. Icahn, Steven D. Miller, Icahn Partners, Icahn Master, Icahn Enterprises GP, Icahn Enterprises Holdings, IPH, Icahn Capital, Icahn Onshore, Icahn Offshore, and Beckton (collectively, the “Icahn Group”). Pursuant to the Nomination Agreement, effective as of March 17, 2021, the Board (i) increased its size to thirteen directors; (ii) appointed Brett Icahn and Steven Miller (collectively, the “Icahn Designees”) to the Board to fill the resulting vacancies; (iii) appointed the Icahn Designees to serve on the Finance and Transactions Committee and the Special Transactions Committees(1); and (iv) nominated the Icahn Designees for election at the Annual Meeting. On August 14, 2025, the Nomination Agreement was terminated and the Icahn Designees resigned from the Board.”
Read it in the proxyopen_in_new
Director Appointment and Nomination Agreement“None of the directors or executive officers of the Company, no proposed nominee for election as a director of the Company, none of the persons who have been directors or executive officers of the Company at any time since the beginning of the Company’s last financial year and no associate or affiliate of any of the foregoing has any material interest, direct or indirect, in any matter to be acted upon at the Meeting other than the election of directors or the amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan.”
Read it in the proxyopen_in_new
Director Appointment and Nomination Agreement“(1) On October 25, 2022, the Board dissolved the Special Transactions Committee, the duties of which committee were assumed by the Board.”
Read it in the proxyopen_in_new
The whole section
As filed
10 paragraphs quoted as filed
Certain Related-Party Transactions“As described in the section titled “Statement of Corporate Governance Practices - Ethical Business Conduct” beginning on page 23, the Board has adopted the Code of Conduct, which sets out the Company’s expectations for the conduct of our employees and directors in their dealings on behalf of the Company. The Conflict of Interest Policy set forth in our Code of Conduct requires that our employees and directors avoid situations in which they have a potential or actual conflict of interest with the Company. In accordance with our Conflict of Interest Policy, any employee, including our officers, involved in any type of relationship described in the Conflict of Interest Policy is required to immediately and fully disclose the relevant circumstances to his or her immediate supervisor, the General Counsel or the Chief Compliance & Ethics Officer, and in accordance with the process set out in the Company’s Conflicts of Interest Standard Operating Procedures. Non-employee directors are required to report their involvement in any type of relationship described in the Conflict of Interest Policy to the Audit and Risk Committee. In addition to reviewing cases where the conflict, or potential conflict, involves a member of the Board, the Audit and Risk Committee reviews transactions or proposed transactions in which an executive officer has an interest that conflicts with the Company’s interests and makes recommendations to the Board regarding any such transaction. Under our Conflict of Interest Policy, examples of outside activities that can create conflicts include:”
Read it in the proxyopen_in_new
Certain Related-Party Transactions“Ownership by a director or employee, or any member of the director’s or employee’s family, of a substantial interest in any concern that does business with the Company, whether as a supplier, dealer or customer, or are a competitor (except in the case of a publicly owned corporation whose securities are traded on the open market).”
Read it in the proxyopen_in_new
Certain Related-Party Transactions“Serving as a director, officer, employee, consultant, advisor, or in any other capacity for any business or other organization with which the Company currently (or potentially) has a business relationship or which is, or can expect to become, a competitor of the Company.”
Read it in the proxyopen_in_new
Certain Related-Party Transactions“Engaging in an outside activity with an individual, business or organization which currently (or potentially) has a competitive or business relationship with the Company where such activity is likely to decrease the impartiality, judgment, effectiveness or productivity expected from an employee.”
Read it in the proxyopen_in_new
Certain Related-Party Transactions“Performance by a director or employee or a member of the director’s or employee’s family of services for any outside concern or individual that does business with the Company.”
Read it in the proxyopen_in_new
Certain Related-Party Transactions“Outside employment which conflicts or might be reasonably expected to conflict with the normal duties of the director or employee.”
Read it in the proxyopen_in_new
Certain Related-Party Transactions“Since January 1, 2025, the Company was involved in the following related-party transactions, which have been approved or ratified by either the Audit and Risk Committee or the Board:”
Read it in the proxyopen_in_new
Director Appointment and Nomination Agreement“On February 24, 2021, the Company entered into a Director Appointment and Nomination Agreement (“Nomination Agreement”) with Carl C. Icahn, Brett M. Icahn, Steven D. Miller, Icahn Partners, Icahn Master, Icahn Enterprises GP, Icahn Enterprises Holdings, IPH, Icahn Capital, Icahn Onshore, Icahn Offshore, and Beckton (collectively, the “Icahn Group”). Pursuant to the Nomination Agreement, effective as of March 17, 2021, the Board (i) increased its size to thirteen directors; (ii) appointed Brett Icahn and Steven Miller (collectively, the “Icahn Designees”) to the Board to fill the resulting vacancies; (iii) appointed the Icahn Designees to serve on the Finance and Transactions Committee and the Special Transactions Committees(1); and (iv) nominated the Icahn Designees for election at the Annual Meeting. On August 14, 2025, the Nomination Agreement was terminated and the Icahn Designees resigned from the Board.”
Read it in the proxyopen_in_new
Director Appointment and Nomination Agreement“None of the directors or executive officers of the Company, no proposed nominee for election as a director of the Company, none of the persons who have been directors or executive officers of the Company at any time since the beginning of the Company’s last financial year and no associate or affiliate of any of the foregoing has any material interest, direct or indirect, in any matter to be acted upon at the Meeting other than the election of directors or the amendment and restatement of the Company’s Amended and Restated 2014 Omnibus Incentive Plan.”
Read it in the proxyopen_in_new
Director Appointment and Nomination Agreement“(1) On October 25, 2022, the Board dissolved the Special Transactions Committee, the duties of which committee were assumed by the Board.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BHC/export.csv") into a cell.